Holen Sie sich die Stockscreener-App
2.66
0.00%
0.00
Handel nachbörslich:
2.66
Schlusskurs vom Vortag:
$2.66
Offen:
$2.66
24-Stunden-Volumen:
583.67K
Relative Volume:
0.42
Marktkapitalisierung:
$342.27M
Einnahmen:
$564.17M
Nettoeinkommen (Verlust:
$37.03M
KGV:
24.29
EPS:
0.1095
Netto-Cashflow:
$-24.46M
1W Leistung:
+9.47%
1M Leistung:
+13.19%
6M Leistung:
-50.92%
1J Leistung:
-8.28%
1-Tages-Spanne:
$2.55
$2.69
1-Wochen-Bereich:
$2.44
$2.69
52-Wochen-Spanne:
$2.04
$7.0771
Organogenesis Holdings Inc Stock (ORGO) Company Profile
Firmenname
Organogenesis Holdings Inc
Sektor
Telefon
781-575-0775
Adresse
85 DAN ROAD, CANTON, MA
Compare ORGO vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORGO
Organogenesis Holdings Inc
|
2.66 | 342.27M | 564.17M | 37.03M | -24.46M | 0.1095 |
TAK
Takeda Pharmaceutical Co Adr
|
15.87 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.24 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.61 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.23 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
578.43 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-28 | Eingeleitet | Lake Street | Buy |
| 2024-02-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-06-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-05-24 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-11-10 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-08-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-01-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-08-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2019-05-02 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-17 | Eingeleitet | Oppenheimer | Outperform |
| 2019-04-11 | Eingeleitet | SunTrust | Buy |
Alle ansehen
Organogenesis Holdings Inc Aktie (ORGO) Neueste Nachrichten
Organogenesis rises as PuraPlyAM succeeds in diabetic foot ulcers - MSN
ORGO stock rallies after hours on clearing regulatory pathway for pain relief treatment - MSN
Organogenesis Holdings stock (US68620V1026): BTIG rating cut puts focus on outlook after Q1 update - AD HOC NEWS
Is Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 Update - Insider Monkey
Organogenesis outlines 2025 revenue guidance of $500M–$525M as CMS policy shift drives growth outlook - MSN
Organogenesis shares jump 20% following positive clinical trial results - MSN
Organogenesis Holdings stock (US68620V1026): FDA warning letter and Nasdaq notice put focus on compl - AD HOC NEWS
Organogenesis Holdings stock (US68620V1026): shares react to earnings and outlook update - AD HOC NEWS
Organogenesis Holdings Inc.Class A (NQ: ORGO - FinancialContent
Organogenesis Holdings stock (US68620V1026): Q1 earnings miss on revenue and EPS - AD HOC NEWS
TradingKey - TradingKey
Organogenesis Holdings Inc. (NASDAQ:ORGO) Q1 2026 Earnings Call Transcript - Insider Monkey
RI skin-maker Organogenesis reports steep Q1 loss amid CMS policy change - The Business Journals
Organogenesis (ORGO) Q1 2026 Earnings Transcript - AOL.com
BTIG downgrades Organogenesis stock rating to neutral on reimbursement headwinds By Investing.com - Investing.com South Africa
BTIG Downgrades Organogenesis(ORGO.US) to Hold Rating - Moomoo
Organogenesis forecasts $270M-$310M 2026 revenue amid prolonged CMS-related recovery - MSN
symbol__ Stock Quote Price and Forecast - CNN
Organogenesis Holdings Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Organogenesis Q1 Earnings Call Highlights - Barchart.com
BTIG downgrades Organogenesis stock rating to neutral on reimbursement headwinds - Investing.com UK
Organogenesis Holdings Inc. (ORGO) Stock Report: Exploring A Potential 216% Upside - DirectorsTalk Interviews
Skin Substitute Market Is Going to Boom Rapidly |Organogenesis - openPR.com
Earnings call transcript: Organogenesis Q1 2026 earnings miss and stock reacts By Investing.com - Investing.com South Africa
Earnings call transcript: Organogenesis Q1 2026 earnings miss and stock reacts - Investing.com Australia
Organogenesis : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Organogenesis Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Organogenesis: Q1 Earnings Snapshot - Barchart.com
ORGO: Revenue fell 58% and net loss widened sharply in Q1 2026 amid regulatory disruption - TradingView
Organogenesis posts $53M loss as wound-care sales drop 63% - Stock Titan
[10-Q] Organogenesis Holdings Inc. Quarterly Earnings Report - Stock Titan
Organogenesis (NASDAQ: ORGO) posts 58% Q1 revenue drop and deeper loss - Stock Titan
Credit Suisse reiterated coverage on Organogenesis Holdings with a new price target - Quantisnow
U.S. Perinatal Tissue-derived Allograft Market Detailed In New - openPR.com
ORGO Price Today: Organogenesis Holdings Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
[ARS] Organogenesis Holdings Inc. SEC Filing - Stock Titan
Organogenesis (NASDAQ: ORGO) details 2026 virtual meeting, pay and audit votes - Stock Titan
Organogenesis Completes Rolling Submission of Biologics License Application for ReNu® - Orthopedics This Week
Organogenesis (ORGO) Projected to Post Earnings on Thursday - MarketBeat
Organogenesis completes biologics license application for knee OA By Investing.com - Investing.com India
Organogenesis completes biologics license application for knee OA - Investing.com UK
Organogenesis Holdings Inc. Completes Biologics License Application Submission for ReNu® to Treat Knee Osteoarthritis - Quiver Quantitative
What's going on with Organogenesis stock on Wednesday? - MSN
Organogenesis (NASDAQ:ORGO) Trading Up 1.7%Time to Buy? - MarketBeat
Finanzdaten der Organogenesis Holdings Inc-Aktie (ORGO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Organogenesis Holdings Inc-Aktie (ORGO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Driscoll Michael Joseph | Director |
Mar 09 '26 |
Buy |
2.67 |
10,000 |
26,688 |
225,707 |
| NUSSDORF GLENN H | Director |
Dec 16 '25 |
Sale |
5.14 |
200,000 |
1,027,060 |
2,565,591 |
5.02%
5.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):